Previous 10 | Next 10 |
Adhera to develop MLR-1019 (armesocarb) as a new class of drug for Parkinson’s Disease (PD), representing the only drug to address both movement and non-movement symptoms of PD Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various p...
Adhera to acquire and develop MLR-1019 (armesocarb), the API in mesocarb – a drug previously sold in Europe for 37 years – for Parkinson’s Disease MLR-1019, a Phase 2-ready product, could have substantial benefits over today’s Parkinson’s drugs, incl...
Baton Rouge, LA, April 23, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera Therapeutics" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce t...
Adhera Therapeutics ( OTCQB:ATRX ): Q3 GAAP EPS of -$0.27. More news on: Adhera Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Company makes significant progress in invest-to-grow strategy RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / November 14, 2019 / Adhera Therapeutics, Inc. (OTCQB:ATRX), an emerging specialty pharmaceutical company that commercializes and delivers effective, patient-centric treatment in chron...
RESEARCH TRIANGLE PARK, NC, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, today announced that it has terminated its previously announced of...
RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 10, 2019 / Adhera Therapeutics, Inc. (OTCQB:ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, announced today that it has entered into a partnership with Indegen...
Co-promote will expand commercialization of Nitrolingual® Pumpspray, a Nitroglycerin Lingual Spray Nitroglycerin has been listed as one of the top 300 most prescribed drugs RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 6, 2019 / Adhera Therapeutics, Inc. (OTCQB:ATRX), a ...
RESEARCH TRIANGLE PARK, NC, July 02, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, today announced that it has terminated its previously announced off...
Thinly traded specialty pharmaceutical company Adhera Therapeutics ( OTCQB:ATRX ) appoints Nancy Phelan as the new Chief Executive Officer of the Company More news on: Adhera Therapeutics, Inc., Healthcare stocks news Read more ...
News, Short Squeeze, Breakout and More Instantly...
Adhera Therapeutics Inc Company Name:
ATRX Stock Symbol:
OTCMKTS Market:
Adhera Therapeutics Inc Website:
3D Systems Corporation (DDD) is expected to report $-0.11 for Q1 2024 ZW Data Action Technologies Inc. (CNET) is expected to report for Q1 2024 Celularity Inc. (CELU) is expected to report for Q1 2023 DMK Pharmaceuticals Corporation (DMKPQ) is expected to report for Q1 2024 Atlant...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...